Radiotherapeutic alternatives for previously irradiated recurrent gliomas
Stephanie E Combs*, Jürgen Debus and Daniela Schulz-Ertner

Address: University Hospital of Heidelberg, Department of Radiation Oncology, Im Neuenheimer Feld 400, 69120 Heidelberg, German
Email: Stephanie E Combs* - stephanie.combs@med.uni-heidelberg.de; Jürgen Debus - juergen.debus@med.uni-heidelberg.de; Daniela Schulz-Ertner - daniela.ertner@med.uni.heidelberg.de
* Corresponding author

Abstract
Re-irradiation for recurrent gliomas has been discussed controversially in the past. This was mainly due to only marginal palliation while being associated with a high risk for side effects using conventional radiotherapy.

With modern high-precision radiotherapy re-irradiation has become a more wide-spread, effective and well-tolerated treatment option. Besides external beam radiotherapy, a number of invasive and/or intraoperative radiation techniques have been evaluated in patients with recurrent gliomas.

The present article is a review on the available methods in radiation oncology and summarizes results with respect to outcome and side effects in comparison to clinical results after neurosurgical resection or different chemotherapeutic approaches.

Background
"Measure a thousand times – and cut once"
This Turkish proverb represents the effort that was put on the issue of re-irradiation in patients with recurrent gliomas. In the past, re-irradiation was thought to be associated with a high incidence of severe treatment-related side effects and was therefore prescribed only reluctantly. A number of reports, however, have suggested that re-irradiation may not be followed by the high incidence of side-effects as feared [1]. Improvement in imaging techniques as well as the establishment of high-precision radiotherapy techniques such as stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) in the clinical routine have enabled the radiation oncologist to precisely define a target volume and to describe it with stereotactic coordinates after targeting with stereotactic methods (measure a thousand times) and to deliver high local doses to this area (and cut once). Therefore, re-irradiation has become a safe and effective means in controlling recurrent gliomas.

It is known that local radiotherapeutic treatment is a main component in the treatment of astrocytomas after primary diagnosis. For low-grade tumors, although the exact time-point of radiotherapy (RT) after primary diagnosis is discussed controversially, most patients are treated at some point during the course of their disease [2,3]. For anaplastic astrocytoma, there is a clear indication for RT after primary diagnosis following neurosurgical resection; presently, combined radiochemotherapy is being evaluated for WHO Grade III tumors (anaplastic astrocytomas, AA). In patients with WHO grade IV astrocytomas, glioblastoma multiforme (GBM), RT is considered the standard postoperative measure, and, if the overall performance status of the patient allows, to be conducted as combined radiochemotherapy with temozolomide [4,5].
Conventional RT is the standard of care radiotherapy approach in patients with progressive gliomas, independently of histology. However, size of the treatment volume varies, from small safety margins of 0.5 to 2 cm for low-grade astrocytomas, to a 2–3 cm safety margin in the treatment volume for anaplastic astrocytomas and high-grade gliomas alike. The total recommended dose amounts to 54 Gy (1.8 Gy qd) for low-grade gliomas, and 60 Gy for GBM, in a fractionation of 5 × 2 Gy/week. Therefore, the majority of patients with recurrent gliomas have been previously exposed to high doses of RT.

Optimization of RT techniques and addition of novel chemotherapeutic substances such as temozolomide have helped significantly increase overall survival for patients with gliomas. Depending on the histologic classification, however, the time to progression may be few months to a number of years, however, tumor progression can be observed in the vast majority of patients. In this situation the neuro-oncologist is faced with a difficult task: Therapy options at the time of recurrence are often limited. Surgery should be considered in all patients, however, gliomas are infiltrative growing tumors and the risk for surgery-associated side effects should be weighed carefully against the possibility and benefit of a surgical intervention [6,7]. Harsh et al. reported median overall survival times of 36 weeks for GBM and 88 weeks for AA after re-operation [8]. A study published by Ammirati et al. corroborated these results with a median survival time of 36 weeks after re-operation [9]. Repeat surgery may not be feasible in a number of patients because of tumor infiltration into eloquent areas of the brain.

Systemic therapies such as chemotherapy have been used widely as single agent or combined treatments, however, often show only modest benefit [10]. Additionally, nowadays, a large group of patients has been exposed to CHT during primary therapy, especially patients with GBM, potentially limiting the efficacy of chemotherapy or leaving the patients with a decreased bone marrow reserve.

In 1999, Wong et al. published a review on outcomes and prognostic factors of patients with recurrent gliomas treated within phase II controlled trials; taken the results from the 8 studies together, the progression-free survival at 6 months was 21%, median progression-free survival 10 months, and median overall survival 30 weeks [11]. These data can be considered base-line data for comparison with subsequent studies in patients with recurrent gliomas. A major brake-through was the oral alkylating agent temozolomide (TMZ) [12,13]. A multicenter phase II study of the Temodal Brain Tumor Group achieved a progression-free survival rate of 46% at 6 months; median progression-free survival was 5.4 months, and overall survival 13.6 months [14]. Alternative dosing-schedules of TMZ, such as the one-week-on/on-week off schedule showed promising results in the past [15]; only recently, results from a phase II study were released with a progression-free rate of 43% at 6 months [16]; median progression-free survival was 24 weeks, and median overall survival 38 weeks.

RT offers a local, non-systemic treatment alternative that should be considered at the time point of recurrence in patients with gliomas. Some alternatives require neurosurgical intervention, such as interstitial brachytherapy, being associated with the feared side-effects and risks of surgery. Other options offer the benefit of a non-invasive treatment, such as conventional external beam RT and high-precision RT techniques.

In the following an overview of RT choices for recurrent gliomas will be given, with description of the technical background, treatment results and ideas for future treatment concepts.

**Conventional external beam RT**

Conventional RT has been used in the past to treat patients with recurrent gliomas. Small patient numbers treated with a second course of RT were published, however, the main effects were seen in at least temporary palliation [17-19]. It has been associated with high rates of side-effects, whereas the clinical outcome was not convincing. Baumann et al. treated 34 patients with recurrent brain tumors with an average of 30 Gy in 3 Gy single fractions as re-irradiation [1]. Of this group, patients with recurrent GBM showed survival from re-irradiation of 2.8 months only, and patients with recurrent LGG 8.5 months, respectively. Veninga et al. published results on 42 patients receiving re-irradiation for recurrent primary brain tumors; the interval between the first and second course of RT was at least 1 year in every patient [20]. RT was delivered with two opposing lateral fields or two wedged fields in orthogonal direction, and a median re-irradiation dose of 46 Gy (range, 4–55 Gy) in a median fractionation of 5 × 2 Gy/week was applied. The median survival and progression-free survival time after re-irradiation were 10.9 months and 8.6 months, respectively. Long-term severe complications were observed only in patients receiving more than 204 Gy cumulative biological equivalent dose (BED).

**Precision radiotherapy**

Over recent years conventional RT was improved and three-dimensionally planned RT was introduced (3D-CRT). Therefore, improved target definition using CT and MRT, as well as using biological parameters such as PET and SPECT, helped improve target.
Stereotactic target localization methods with highest precision (high precision radiotherapy) offer optimal sparing of surrounding normal tissue. The principle of stereotactic RT was developed in the 1950s and 1960s, when Lars Leksell developed the so called Gamma Knife for the Stereotactic Radiosurgery (SRS) of brain tumors [21-23]. In the 1980s linear accelerators (LINAC) were also equipped for stereotactic radiation treatments. Stereotactic irradiation has been implemented widely in the clinical routine and has been proven to be effective for brain metastases, meningioma, acoustic neuroma and primary brain tumors [24-26]. The required dose can be applied in a single fraction as Stereotactic Radiosurgery (SRS), or the total dose can be applied in a number of fractions, as Fractionated Stereotactic Radiotherapy (FSRT). Both modalities have been used effectively for the treatment of recurrent gliomas.

**Stereotactic Radiosurgery (SRS)**

SRS is a highly conformal, non-invasive, precision radiotherapy technique. Due to its accuracy and steep dose gradients at the field it is possible to deliver a prescribed dose to a defined target volume while sparing surrounding healthy tissue, including organs at risk [25,27,28].

Commonly, SRS is limited to smaller treatment volumes to prevent high incidences of radiation-induced injury; it is known that the risk of treatment-related side effects increases with target size as well as an increase in RT dose.

Shrieve et al. observed median survival times of 10.2 months after SRS for recurrent GBM; significant prognostic factors included tumor size and age [29]. At the Department of Radiation Oncology in Heidelberg, Germany, we treated 32 patients with recurrent glioma with SRS; a median dose of 15 Gy was applied to a median target volume of 10 ml. During follow up, no severe treatment related side effects could be observed, and the median survival from SRS was 10 months [27]. However, other groups have reported higher incidences of treatment related side effects, especially in larger target volumes. In a study published by Hall et al., 14% of the patients developed radiation-induced necrosis, while survival calculated from SRS was 8 months [30]. The comparably high rate of severe side-effects might be due to the relatively larger volumes (median 28 cm³) treated with SRS. However, the higher rate of necrosis in the study published by Hall et al. might also be due to the higher median dose of 20 Gy applied. The University of Minnesota, Department of Radiation Oncology published results of SRS in 46 patients with recurrent gliomas; a median dose of 17 Gy was prescribed to a median target volume of 30 ml; 14 out of 46 (30%) patients developed severe late complications such as necrosis [31].

A selection of reports on SRS in recurrent gliomas can be found in table 1. Data conclude that SRS is a safe and feasible treatment alternative, however, due to the higher risk of severe treatment-related side effects with increasing target size, SRS should be reserved for smaller lesions.

**Fractionated Stereotactic Radiotherapy (FSRT)**

FSRT is another non-invasive precision RT technique: The required therapeutic dose is divided into a number of fractions. By exploiting the radiobiological advantage of fractionation, the risk of side effects to normal tissue can be minimized. FSRT can be applied safely for very small target volumes as an alternative to SRS; moreover, for large tumors, FSRT can also be performed safely and effectively without the high risk of side effects associated with SRS in such tumors.

A number of groups have studied FSRT in patients with recurrent gliomas (table 3). A very large series of patients treated at the Department of Radiation Oncology at the University of Heidelberg consisted of 172 patients treated with FSRT for recurrent gliomas [32]. In this group, median overall survival of 21 months, 50 months and 111 months could be observed for GBM, anaplastic astrocytoma, and other histology, respectively.

### Table 1: Series of patients with recurrent gliomas treated with stereotactic radiosurgery (SRS).

| Author                | Pt. Number | Histology          | Median Dose (Gy) | Tumor size (ml; median) | Median survival (months) | Rate of Severe Toxicity/Reoperation rate (%) |
|-----------------------|------------|--------------------|------------------|------------------------|--------------------------|---------------------------------------------|
| Chamberlain et al, 1994 | 20         | 5 GBM, 10 AA, 5 other | 13.4            | 17                     | 8                        | -                                           |
| Cho et al., 1999      | 46         | 27 GBM/19 AA       | 17              | 10                     | 11                       | 22%                                         |
| Combs et al., 2005    | 32         | GBM                | 15              | 10                     | 10                       | -                                           |
| Hall et al., 1995     | 35         | 26 GBM, 9 AA       | 20              | 28                     | 8                        | 31%                                         |
| Kondziolka et al., 1997 | 23     | AA                 | 15.6            | 6                      | 31                       | 23%                                         |
| Kondziolka et al., 1997 | 19       | GBM                | 15              | 6.5                    | 30                       | 19%                                         |
| Shrieve et al., 1995  | 86         | GBM                | 13              | 10.1                   | 10.2                     | 22%                                         |
toma or low-grade glioma recurrences, respectively. The rate of severe radiation induced side effects was very low.

Other series using FSRT for recurrent gliomas are summarized in table 2. Hudes and colleagues reported a median survival of 10.5 months in a series of 20 patients treated with FSRT, with no radiation-induced late toxicity [33]. 45% of the patients improved with respect to neurological symptoms; however, tumor volumes were comparably small with 12.7 ml.

**Hypofractionated stereotactic radiotherapy (H-FSRT)**

Hypofractionated stereotactic radiotherapy (H-FSRT) is characterized by potentially lower toxicity than SRS, however, compared to FSRT, the risk for side effects seems increased due to the higher single doses (table 3). A major advantage of the fewer treatment fractions is the reduction of overall treatment time which is an especially important issue in terminally ill patients. Shepherd et al. treated 36 patients with H-FSRT with total doses between 20 and 50 Gy, in single fractions of 5 Gy. A major predictor of radiation damage was a total dose > 40 Gy; 36% of the patients developed steroid-dependent toxicity, and 6% of the patients required re-operation [34]. A dose escalation study published by Hudes et al. applied doses from 24 Gy to 35 Gy in median fractions of 3 Gy to 20 patients; no grade 3 toxicities could be documented, and no reoperation due to toxicity was required. Median survival from H-FSRT was 10.5 months.

A recent study published by Vordermark et al. reports on 19 patients with recurrent gliomas treated with H-FSRT [35]. The median survival from H-FSRT was 9.3 months, with 16% survival at 2 years, and a very low rate of side-effects. The strongest predictors for survival were total dose (< 30 Gy vs. 30 Gy) as well as tumor histology.

For each patient, the choice, whether SRS, H-FRST or FSRT is the appropriate treatment, has to be made individually, depending on the size of the lesion, the location and the previously applied RT dose and target volume. In general, it should be considered that increasing fraction size can be associated with an increase in treatment-related side effects (Fig. 1). Besides lesion size, there is a response-relationship the prescribed dose and the risk for severe treatment-related side effects [36]. Flickinger et al. proposed a model to estimate complication risk for linear accelerator radiosurgery using an integrated logistic formula [37]: Dose-volume isoeffect curves were calculated for a 3% risk of brain necrosis. The previous analysis of Kjellberg however, calculated a risk of 1% for a lesion with a diameter of 20 mm and a prescribed dose of 24 Gy. Additionally, with respect to the clinical situation, it is often difficult to distinguish between tumor progression and necrosis; moreover, is must be kept in mind that, according to the initial definition of SRS postulated by Leksell in 1951, is the aim to induce a circumscribed necrosis. Therefore, necrosis is per se not a complication of SRS, but a therapeutic effect. Therefore, the crucial aspect is that no healthy tissue should be destroyed by SRS, potentially leading to severe clinical symptoms. Several studies report rates of necrosis and/or reoperation rates, however, not in all cases can be determined whether reoperation was due to tumor pro-

| Author            | Pt. Number | History (mL; median) | Median Dose (Gy) | Median Fraction Size (Gy) | Median survival (months) | Rate of Severe Toxicity/Reoperation rate (%) |
|-------------------|------------|---------------------|------------------|--------------------------|--------------------------|---------------------------------------------|
| Cho et al., 1999  | 15 (10)    | GBM (AA)            | 74               | 37.5                     | 2.5                      | 11                                          | 12%                                         |
| Combs et al., 2005| 71         | LGG                 | 49.3             | 36                       | 2                        | 111                                         | -                                           |
| Combs et al., 2005| 42         | AA                  | 36               | 2                        | 50                       | -                                           | -                                           |
| Combs et al., 2005| 59         | GBM                 | 36               | 2                        | 21                       | -                                           | -                                           |

Table 2: Series of patients with recurrent gliomas treated with fractionated stereotactic radiotherapy (FSRT).

| Author                        | Pt. Number | History (mL; median) | Median Dose (Gy) | Median Fraction Size (Gy) | Median survival (months) | Rate of Severe Toxicity/Reoperation rate (%) |
|-------------------------------|------------|---------------------|------------------|--------------------------|--------------------------|---------------------------------------------|
| Ernst-Stecken et al., 2006    | 15         | GBM                 | 22.4             | 35                       | 7                        | -                                           | 0%                                          |
| Hudes et al., 1999            | 19 (1)     | GBM (AA)            | 12.6             | 30                       | 3                        | 10.5                                        | 0%                                          |
| Laing et al., 1993            | 22         | GBM                 | -                | 30–50 (range)            | 5–6 (range)              | -                                           | -                                           |
| Selch et al., 2000            | 15 (3.3)   | GBM (AA/LGG)        | 12               | 25                       | 4–6 (range)              | 6.7                                         | 0%                                          |
| Shepherd et al., 1997         | 29 (7)     | GBM/AA (LGG)        | 24               | 20–50 (range)            | 5                        | 11 (GBM/AA)                                | 36%                                         |
| Vordermark et al., 2005       | 10 (19)    | II or III           | 15               | 30                       | 5                        | 13.5                                        | 26%                                         |
| Vordermark et al., 2005       | 9 (19)     | IV                  | 15               | 30                       | 5                        | 7.4                                         | -                                           |
Progression, or mainly due to symptomatic radiation-induced necrosis.

Thus, for each clinical situation the choice whether SRS should be applied, with the advantage of short treatment times, however, with a higher risk of side effects, or whether FSRT or H-FSRT is chosen, with a lower toxicity-risk but with a longer treatment course, should be weighed against each other, taking into account such factors as patients’ performance status, size and location of the lesion as well as previous therapies. H-FSRT with fewer large fractions as compared to FSRT may shorten overall treatment time, but may compromise too much of the potential advantages of fractionation.

**Intensity modulated radiotherapy (IMRT)**

IMRT is another modern high-precision RT technique that offers advantages for patients with complex tumor or target volumes such as skull base or paraspinal tumors, in close vicinity to organs at risk. In such cases, better dose conformality and sparing of normal tissue can be achieved as compared to conventional conformal RT [38-40]. A major down side is considered to be an increased dose inhomogeneity within the target volume, and in some cases, an increased low dose bath to surrounding healthy tissue. Therefore, the use of IMRT for the irradiation of gliomas cannot be considered to be superior to FSRT, and the increased preparation time needed may not lead to an improved patient treatment. However, a number of groups have studied IMRT in gliomas [41-43]. Voynov et al. treated 10 patients with recurrent gliomas with IMRT in a hypofractionated regimen [43]: In 5 Gy single doses, median total doses of 30 Gy were delivered. After re-irradiation with IMRT, the median survival time was 10.1 months.

**Interstitial radiotherapy**

Interstitial RT using radioactive seeds as permanent or temporary brachytherapy was performed in the 1980s in a large number of patients using high-activity iodine-125 (125I) or iridium-192 (192I; table 4).

Implantation of 125I seeds for recurrent glioma has been shown to offer excellent palliation in a majority of patients and a significant level of long-term survival. 125-I seeds can be used for permanent or for temporary implants. In a number of cases improved survival was seen, however, along with high rates of radionecrosis [44-

---

**Table 4: Series of patients with recurrent gliomas treated with I-125 seed implants.**

| Author          | Pt. Number | Histology | (Median) Dose (Gy) | Median survival (months) | Rate of Severe Toxicity/Reoperation rate (%) |
|-----------------|------------|-----------|--------------------|--------------------------|---------------------------------------------|
| Gaspar et al., 1999 | 37 (22)    | GBM (AA)  | 100                | 10.5                     | 44%                                         |
| Halligan et al, 1996 | 22(4)      | GBM (AA)  |                    | 16                       | 5%                                          |
| Larson et al., 2004 | 38         | GBM       | 150–500            | 12.0                     | 10%                                         |
| Patel et al., 2000 | 40         | GBM       | 120–160            | 11.8                     | 0%                                          |
| Gutin et al., 1987 | 18         | GBM       |                    | 13                       | 41%                                         |
| Leibel et al., 1989 | 45         | GBM       | 70                 | 12.5                     | 49%                                         |
| Leibel et al., 1989 | 50         | AA        | 70                 | 18.7                     |                                             |
| Shrieve et al., 1995 | 32         | GBM       | 50                 | 11.5                     | 44%                                         |
| Simon et al., 2002 | 42         | GBM       | 40–60              | 12.5                     | 24%                                         |
| Sneed et al, 1997  | 45         | AA        | 64                 | 12.3                     | 53%                                         |
| Sneed et al, 1997  | 66         | GBM       | 64                 | 11.7                     | 46%                                         |
| Gabayan et al. 2005 | 24         | GBM       | 53                 | 9.1                      | 33%                                         |
| Gabayan et al. 2006 | 80         | GBM       | 60 Gy              | 8.9                      | 2%                                          |
| Gabayan et al. 2006 | 15         | Non-GBM   | 60 Gy              | 10.9                     |                                             |

---

**Figure 1**

Severe treatment-related toxicity in patients with recurrent gliomas treated with FSRT, SRS of hypofractionated RT.
Seed implants can produce inhomogeneous radiation dose distributions, associated with repeated operations for radionecrosis occurring in up to 64% of patients treated with interstitial implants [47-50]. Stereotactic placement of multiple sources around a surgical cavity is a technically challenging procedure, most likely explaining the frequently occurring area of inadequate dosing, suboptimal dosimetry could explain the relatively poor results observed in some trials [46,51]. The use of low-dose-rate (LDR) interstitial brachytherapy with permanent 125I implants has reduced the rate of severe complications including symptomatic radionecrosis. Permanent LDR brachytherapy does not require stereotactic frame placement or the drilling of multiple holes in the skull for seed placement. However, as with high-dose-rate (HDR)-temporary implants optimal dosimetry may be difficult to achieve. Survival in patients with recurrent GBM treated with this technique is comparable to that observed in similar patients treated with brachytherapy using temporary high-activity implants [52,53].

Permanent brachytherapy is performed immediately after neurosurgical resection, using 125I sources placed around the surgical cavity and implanted into the surrounding brain tissue. The total dose rate over the lifetime of the radiation sources lies between 100 and 400 Gy, however, the dose rate is much lower than for temporary brachytherapy, during which 50 to 65 Gy are applied over 4 to 12 days. For GBM, median survival times after permanent brachytherapy range from 10.5 months to 12 months [52-54]. Patel et al. treated 40 patients with recurrent GBM with permanent interstitial implants, with a dose between 120 and 160 Gy; none of the patients developed severe side effects such as radiation necrosis or injury, and survival after implantation was 47 weeks [53].

Using temporary brachytherapy, the groups of Sneath (n = 66 GBM, n = 45 AA), Shrieve (n = 32 GBM) and Chan (n = 24 GBM) could obtain median survival times of 11.7, 11.5, 12.3 and 9.1 months, respectively [29,55,56]. Median doses between 50 and 64 Gy were applied, and reoperation rates after treatments were between 8% and 53%. Leibel et al. reported on a series of 95 patients with recurrent malignant gliomas treated with brachytherapy after initial conventional RT (dose range 40–72 Gy); for a selected group of patients, interstitial implantation of 125I sources (dose range, 52.7 – 150 Gy) resulted in a median survival of 18.7 and 12.5 months for anaplastic astrocytomas and GBM, respectively [47]. In 49% of the patients reoperation was required due to treatment-associated necrosis within the high-dose area of the implantation. Gutin et al. compared the survival of 18 patients treated with 125I implants for recurrent GBM with 42 historical controls treated with chemotherapy. Median survival in the 125I-group was 52 weeks as compared to 28 weeks after chemotherapy [57].

A novel alternative temporary brachytherapy technique is intracavitary low-dose rate (LDR) brachytherapy, also referred to as Glia-site brachytherapy [59]. It is performed with an expandable balloon catheter (GliaSite Radiation Therapy System (RTS), Cytyc Surgical Products, Palo Alto, CA, USA) which is placed into the resection cavity at the time of tumor resection or debulking. The GliaSite system offers balloons with 2.3 and 4 cm diameter. After a period of 2 to 4 weeks after surgery the catheter is filled with an aqueous solution of organically bound 125I (Iotrex [sodium 3-(125I)-iodo-4-hydroxybenzenesulfonate]) for a predetermined amount of time of about 3 to 6 days until the calculated dwell time has been achieved. Thereafter, the Iotrex is retrieved transcutaneously. The feasibility and safety of the system was published by Tatter et al.; the implantation, radiation delivery as well as the expantation were carried out without any serious side effects [59]. An initial report on the system was published by Shrieve et al. in 1995 [60].

The target volume for GliaSite brachytherapy is considered to be the residual enhancing tissue identified in postoperative MRI-scans, and it is calculated to receive at least 100% of the prescribed dose. GliaSite functions as a single spherical source of low-dose rate radiation and the photon energy of 125I (27–35 keV photons) result in rapid attenuation over short distances via the photoelectric effect, which leads to a steep dose fall-off and a typical prescription depth of 0.5 to 2 cm.

Gabayan et al. published a retrospective analysis of 95 patients with recurrent WHO grade III and IV gliomas treated with GliaSite [61]. The median dose applied was 60 Gy using balloon sizes between 2.0 and 4.0 cm and a median survival time calculated from re-operation was 36.3 weeks. Little information is given on the resection status and its impact on outcome after GliaSite brachytherapy; patients undergoing total or at least subtotal resection are known to present with more favourable outcomes, and no data is provided on the number of patients that were treated a biopsy only. Therefore, no conclusion
can be made as to which patients profit most from GliaSite brachytherapy.

Chan et al. treated 24 patients with Glia Site brachytherapy, with a rate of 8% of symptomatic necrosis and survival times of 9.1 months [56].

**Intraoperative electron radiotherapy (IOERT)**

IOERT is implemented in clinical routine especially for rectal carcinoma, sarcomas or for pancreatic carcinomas [62,63]. Only a limited number of centers are equipped with dedicated IOERT machines. Irradiation is performed in the operating room, and RT is applied directly into the resection cavity.

Few data exist on IOERT in patients with gliomas. However, the rational of local dose escalation by an electron boost directly into the surgical cavity, especially for unresectable or only partially resectable tumors, seems a promising treatment alternative.

First promising results on IOERT were published by the groups of Sakai and Matsutani in patients with primary malignant brain tumors, however, could not be reproduced by European studies so far [64-66]. Therefore, for primary gliomas, addition of IOERT to conventional treatment (surgery and RT) has not proven to significantly improve outcome [67,68].

However, for recurrent gliomas, a number of studies have shown that IOERT is safe and feasible with acceptable results without significantly increasing surgery times. A major downside is the “invasive” nature, i.e. IOERT can only be performed in the neurosurgical setting.

Japanese data reported by Hara et al. on 6 patients with recurrent gliomas showed superior results in patients treated with surgery and IOERT than surgery alone or in combination with chemotherapy [69]. Shibamoto et al. evaluated the feasibility of IOERT in 19 patients with recurrent brain tumors of different histologies [70]. RT had been part of the initial treatment with a mean dose of 53 Gy (range, 17–65 Gy). IOERT was applied in a dose range of 23–40 Gy. During follow up, three cases of symptomatic brain necrosis occurred, one of which was fatal.

For the subgroup of patients with anaplastic astrocytomas or GBM, median survival from IOERT was 12 months.

Ortiz de Urbina published results on IOERT in 9 patients with recurrent gliomas; the actuarial 18 months survival rate and survival time was 47% and 13 months in this group. The median time to tumor progression after IOERT was 11 months. IOERT was applied in single doses of 10–20 Gy, and no IOERT related mortality was observed [71].

At the University Hospital of Muenster in Germany IORT has been performed since 1992 for gliomas. In total 71 patients were treated, of which 19 were treated for recurrent gliomas [67]. In these patients, electron-beam IORT was performed with 15–25 Gy, depending on size of the lesion, doses and field location of previously performed RT as well as the RT dose applied prior to IORT. Disease-free survival in this subgroup was 12.45 months. Perioperative complications were not increased in the IORT group, however, no clear statement could be made on the incidence of severe side-effects such as brain necrosis.

**Radio-chemotherapy**

To further optimize treatment results obtained by re-irradiation, chemotherapy might be added to RT. However, this combined approach is likely to increase side effects, especially in substances with strong radiosensitizing potential. As re-irradiation alone is applied with caution, radio-chemotherapy as re-irradiation is performed even more restricted.

Only few groups have studied combined re-irradiation and chemotherapy in recurrent gliomas (table 5).

Wurm et al. combined HFSRT with topotecan chemotherapy in 25 patients; histology was AA in 20% and GBM in 80%, respectively. RT was applied in a median dose of 30 Gy in 5–6 fractions [72]. Overall survival was 14.5 months, 12% of the patients developed adverse RT-induced side effects. Topotecan was prescribed in a dose of 1.1 mg/m2 qd as continuous infusion during H-FSRT followed by up to 48 courses of chemotherapy.

| Author          | RT-Technique | Chemotherapy | Pt. Number | Histology | Tumor size (ml; median) | Median Dose (Gy) | Median Fraction Size (Gy) | Median survival (months) | Rate of Severe Toxicity/Reoperation rate (%) |
|-----------------|--------------|--------------|------------|-----------|-------------------------|------------------|--------------------------|--------------------------|-------------------------------------------|
| Arcicosa et al., 1999 | CH-EBRT      | CCNU         | 24 (7)     | GBM (AA)  | -                       | 34.5             | 1.5                      | 13.7                     | -                                         |
| Glass et al., 1997    | CH-HSFRT     | Cisplatin    | 13 (7)     | GBM (AA)  | 14                      | 35–42 (range)    | 3.5–6 (range)            | 13.7                     | -                                         |
| Lederman et al., 2000 | CH-HSFRT     | Paclitaxel   | 88         | GBM       | 32.7                    | 18–36 (range)    | 4–9 (range)              | 7                        | 11%                                       |
| Wurm et al., 2006     | CH-HSFRT     | Topotecan    | 5 (25)     | III       | 16.5                    | 30               | 5                       | 21.3                     | -                                         |
| Wurm et al., 2006     | CH-HSFRT     | Topotecan    | 20 (25)    | IV        | 16.5                    | 30               | 5                       | 7.9                      | -                                         |

Table 5: Series of patients with recurrent gliomas treated with radio-chemotherapy.
Glass et al. combined HFSRT with cisplatin weekly (40 mg/m²) in 20 patients with recurrent AA and GBM [73]. A median survival of 12.7 months was observed, with a rate of 15% of necrosis at re-operation. Another group combined HFSRT with paclitaxel weekly (120 g/m²) in 88 patients with GBM; median overall survival was 7 months [74]. Only 8% presented with necrosis at re-operation.

Thirty-one patients with recurrent GBM and AA were treated with re-irradiation and lomustine (CCNU) at the Department of Radiation Oncology in Aviano, Italy [75]. Oral administration was begun concomitantly with re-irradiation and was repeated every 6 weeks. Toxicity was moderate, however, also treatment results were observed with only modest subjective and objective response rates; on the other hand, survival from relapse was remarkable at 13.7 months.

Chamberlain et al. combined ¹²⁵I-brachytherapy with concurrent cisplatin; in 16 patients stereotactically placed catheters were afterloaded with ¹²⁵I sources with a median 50 Gy minimum treatment volume dose during a 100 hour period along with cisplatin 20 mg/m² qd over 5 days. Early complications included headache, seizures and worsening of neurological symptoms; late complications included radiation-induced necrosis in 9 patients requiring reoperation [76]. A partial response was seen in 5 patients, stable disease in 7 and progressive disease in 3 patients over a median follow-up time of 9.5 months.

**Hyperthermia**

It is known that an increase in temperature to a certain level enhances the anti-tumor action of chemotherapy and radiotherapy, alike [77,78]. For therapeutic hyperthermia, temperatures between 44°C – 46°C are considered to be effective. Above this temperature, coagulation necrosis occurs, which is a principle used in thermo- or radio-frequency-ablation. In oncological concepts, the direct cytotoxic effect of hyperthermia is anticipated, but also the chemo- and radiation-sensitizing effect of higher temperature.

Therefore, there was hope that hyperthermia might help improve outcome in patients with gliomas. Sneed et al. recruited 112 patients within 5 years with tumor manifestations not exceeding 5 cm in diameter [79]. Within this two armed study, patients in both arms were treated with brachtherapy; in one arm, 30 min prior to brachtherapy hyperthermia was applied. Progression-free survival could be increased from 33 to 49 weeks in the group treated with hyperthermia, and overall survival could be extended 9 weeks by application of hyperthermia; 2-year survival rates were 0% and 10% for the two groups, respectively. However, technical setup and treatment procedures were complex.

**Proton radiotherapy/Carbon ion radiotherapy**

Particle therapy such as proton and carbon ion treatment has been implemented for patient treatment over the last years. In certain tumor entities carbon ion RT has been shown to offer significantly better tumor control as compared to photon RT [80,81]. Protons and carbon ions as well are characterized by a distinct physical so called inverse dose profile; this results in a high dose deposition very locally in the so-called Bragg Peak, and a steep dose fall-off thereafter. Additionally, carbon ion beams offer an increased relative biological effectiveness (RBE) which is known to be especially beneficial in radioresistant, hypoxic and/or slow-growing tumors.

Worldwide, a number of centers offer particle beams; at the University of Heidelberg, carbon ion radiotherapy is performed at the Gesellschaft für Schwerionenforschung (GSI) in Darmstadt. In 2007, the Heidelberg Ion Therapy Center will take up patient treatment offering proton and carbon ion RT. Preliminary data from Japan have shown effectivity of C₁₂ in patients with GBM, however, in this series, no concomitant chemotherapy was applied which is considered the standard for the treatment of primary GBM [82]. Since further investigation of C₁₂ in patients with gliomas is warranted, implementation of C₁₂ to recurrent astrocytomas will be evaluated in a clinical setting at the Department of Radiation Oncology in Heidelberg, Germany, in the near future.

**Conclusion**

In the past, a number of attempts have been made to salvage patients with recurrent gliomas with a second course of radiotherapy. A number of invasive and non-invasive techniques are available and have proven effectivity in recurrent gliomas. Certainly, every patient confronts us with an individual setting, including tumor size, location, previous treatments as well as performance status and clinical symptoms. The choice as to which modality should be applied has to be made individually for each patient, reflecting possibilities, potential benefit and side-effects.

For all RT modalities, close vicinity to sensitive risk structures is a main obstacle for a second course of RT since the risk for severe side effects, confining quality of life or jeopardizing even vital organ functions, are high due to the limited tolerance dose [83]. Especially for SRS as well as invasive procedures such as brachtherapy, the potential toxicity becomes of major concern if the tumor becomes larger or is located close to eloquent structures, such as the optic pathway, basal ganglia, motor or speech areas or the brain stem.

Using modern highly conformal RT techniques, precise dose application to a defined target volume is possible
while the surrounding normal tissue can be spared, in a non-invasive approach. Therefore, treatment related toxicity can be minimized, while treatment results can be improved. Re-irradiation using high precision radiotherapy offers significant benefit, at least for a subgroup of patients. For each patient, the fractionation scheme must be chosen individually.

However, it is not a curative treatment and further improvement is needed urgently. Further investigation of combined radiochemotherapy as well as novel RT modalities such as carbon ion RT are needed.

Competing interests
The author(s) declare that they have no competing interests.

Authors’ contributions
SEC and DSE collected the data useful for the analysis; SEC and DSE performed the analysis and wrote the manuscript. JD revised the article critically for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements
All funding for the study and for the manuscript preparation was taken over by the Department of Radiation Oncology, University Hospital of Heidelberg, Heidelberg, Germany.

References
1. Bauman GS, Sneed PK, Wara WM, Stalpers LJ, Chang SM, McDermott MW, Gutin PH, Larson DA: Reirradiation of primary CNS tumors. Int J Radiat Oncol Biol Phys 1996, 36:433-441.
2. Karim AB, Maat B, Hatlevoll R, Menten J, Rutten EH, Markesbery WR, Haack D, Tibbs PA, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO: A randomized trial on dose-response in radiation therapy of low-grade gliomas. J Neurosurg 2005, 103:316-319.
3. Newlands ES, Stevens MF, Wedge SR, Brock C: Temozolomide for recurrent glioblastoma. A review of its discovery, pre-clinical development and clinical trials. Cancer Treat Rev 1997, 23:35-61.
4. Wang FK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yimbali N, Dugan M, Zakoien S, Levin VA: Multicentre phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 1999, 17:2762-2771.
5. Wick W, Steinbach JP, Kuiper WM, Dichgans J, Bamberg M, Weller M: One week on/one week off of a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004, 62:2113-2115.
6. Horns J, Webber MM: Retreatment of brain tumors. Radiology 1990, 177:222-325.
7. Veninga, T, Radiat Oncol Biol Phys 1998, 46:797-803.
8. Leksell L, Stereotactic radiosurgery. J Neurol Neurosurg Psychiatry 1983, 46:797-803.
9. Leksell DG: Stereotactic radiosurgery. Present status and future trends. Neurol Res 1987, 9:60-68.
10. Leksell L: The stereotactic method and radiosurgery of the brain. Acta Chir Scand 1951, 103:316-319.
11. Combes SE, Thilmann C, Debus J, Schulz-Ertner D: Long-term outcome of stereotactic radiosurgery (SRS) in patients with acoustic neuromas. Int J Radiat Oncol Biol Phys 2006, 64:1341-1347.
12. Combes SE, Schulz-Ertner D, Thilmann C, Edler D, Debus J: Treatment of cerebral metastases from breast cancer with stereotactic radiosurgery. Strahlenther Onkol 2004, 180:590-596.
13. Loeffler JS, Shrieve DC, Alexander E: Radiotherapy for glioblastoma multiforme: the importance of selection criteria. Int J Radiat Oncol Biol Phys 1994, 30:713-733.
14. Loeffler JS, Shrieve DC, Alexander E: III: Radiosurgery for glioblastoma multiforme: the importance of selection criteria. Int J Radiat Oncol Biol Phys 2002, 53:917-921.
30. Hall WA, Djillalian HR, Spereduto PW, Cho KH, Gerbi BJ, Gibbons JP, Rohr M, Clark HB: Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 1995, 13:164-168.

31. Cho KH, Hall WA, Gerbi BJ, Higgins PD, McGuire WA, Clark HB: Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas. Int J Radiat Oncol Biol Phys 1999, 45:1133-1141.

32. Combs SE, Thilmann C, Edler L, Debus J, Schulz-Ertner D: Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. J Clin Oncol 2005, 23:8863-8869.

33. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Pintilie M, Bernstein M: Intensity-modulated radiation therapy with an integrated boost to the macroscopic tumor volume in the treatment of malignant gliomas. J Clin Oncol 2003, 21:1489-1495.

34. Shepherd SF, Laing RW, Cosgrove VP, Warrington AP, Hines F, Ashcroft M: Immediate-iodine-125 sources for the treatment of patients with recurrent malignant gliomas. J Neurosurg 1995, 83:105-108.

35. Sneed PK, McDermott MW, Gutin PH: Intensity-modulated radiation therapy with an integrated boost to the macroscopic tumor volume in the treatment of malignant gliomas. J Neurosurg 1996, 85:153-154.

36. Sneed PK, McDermott MW, Gutin PH: Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurosurgery 1999, 45:341-351.

37. Vordermark D, Kolbi O, Ruprecht K, Vince GH, Bratengeier K, Flenje M: Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer 2005, 5:55.

38. Wen PY, Alexander E III, Black PM, Fine HA, Riese N, Levin JM, Coleman CN, Loeffler JS: Long term results of stereotactic brachytherapy used as the initial treatment of patients with glioblastomas. Cancer 1994, 73:3029-3036.

39. Prados MD, Gutin PH, Phillips TL, Wara WM, Sneek PK, Larson DA, Lamb SA, Ham B, Malec MK, Wilson CB: Intertitial brachytherapy for newly diagnosed patients with malignant gliomas: the UCSF experience. Int J Radiat Oncol Biol Phys 1992, 24:593-597.

40. Ling CC, Anderson LL, Shipley WU: Dose inhomogeneity in interstitial implants using 125I seeds. Int J Radiat Oncol Biol Phys 1979, 5:419-425.

41. Selker RG, Shapiro WR, Burger P, Blackwood MS, Arena VC, Gilder JC, Faktin MG, Meyler J, Olson J, Robertson JT, Barnett GH, Bloomfield S, Albright RH, Hochberg FH, Hiesiger E, Green S: The Brain Tumor Cooperative Group NIH Trial 87-01: a randomized comparison of surgery, external radiotherapy, and carbustine versus surgery, interstitial radiotherapy boost, external radiotherapy, and carbustine. Neurosurgery 2002, 51:343-355.

42. Larson DA, Suplica JM, Chang SM, Lambert KR, McDermott MW, Sneek PK, Prados MD, Wara WM, Nicholas MK, Berger MS: Permanent iodine 125 brachytherapy in patients with progressive or recurrent glioblastoma multiforme. Neurosurgery 2004, 6(1):119-126.

43. Patel S, Breneman JC, Warnick RE, Albright RE Jr., Tobler WD, van Loveren HR, Tew JM Jr.: Permanent iodine-125 interstitial implants for the treatment of recurrent glioblastoma multiforme. Neurosurgery 1999, 45:123-128.

44. Gaspar LE, Zamanoro LJ, Samsa F, Fontanels J, Ezzel GE, Yakar DA: Permanent 125Iodine implants for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1999, 43:977-982.

45. Sneed PK, McDermott MW, Gutin PH: Intertstitial brachytherapy for recurrent glioblastoma multiforme. Semin Radiat Oncol 1997, 13:157-166.

46. Chan TA, Weingart JD, Parisi M, Hughes MA, Olivi A, Borzilly S, Alahakone D, Deterio NA, Wharam MD, Kleinberg L: Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy. Int J Radiat Oncol Biol Phys 2005, 61:133-139.

47. Gutin PH, Leibal SA, Wara WM, Choucair A, Levin VA, Phillips TL, Silver P, Da S V, Edwards MS, Davis RL.: Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources. J Neurosurg 1987, 67:864-873.

48. Simon JM, Suvait P, Boissiere G, Haxby D, Teip B, Newman C, Valery CA, Delatre JY, Dormont D, Balleit F, Mazeron JJ: Brachytherapy of glioblastoma recurring in previously irradiated territory: predictive value of tumor volume. Int J Radiat Oncol Biol Phys 2002, 53:677-684.

49. Tatter SB, Shaw EG, Robinson ML, Karvelis KC, Kleinberg L, Weingart J, Olson JJ, Crocker IR, Brem S, Pearlman JL, Fisher JD, Carson K, Grossman SA: An inflatable balloon catheter and liquid 125I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. Int J Radiat Oncol Biol Phys 2003, 52:297-303.

50. Shrieve DC, Laperriere NJ, Leung PM, McGuire WA, Clark HB: Single dose versus fractionated stereotactic radiotherapy for recurrent malignant gliomas. J Clin Oncol 1995, 13:164-168.

51. Laperriere NJ, Leung PM, McKenzie IM, Milosevic M, Wong S, Glen J, Pintilie M, Bernstein M: Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. Int J Radiat Oncol Biol Phys 1998, 41:1005-1011.

52. Leibal SA, Gutin PH, Wara WM, Phillips TL, Larson DA, Edwards MS, Lamb SA, Ham B, Washington BA, Barnett C: Survival and quality of life after interstitial implantation of removable high-activity iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989, 17:1129-1139.
65. Sakai N, Yamada H, Andoh T, Takada M, Hirata T, Funakoshi T, Doi H, Yanagawa S: [Intraoperative radiation therapy for malignant glioma]. J Neurooncol 1991, 18:174-179.

66. Matsuzani M, Nakamura O: [Advances of surgery and radiation therapy of glioblastoma and metastic tumor]. Gan To Kagaku Ryoho 1991, 18:321-328.

67. Schueler P, Micic O, Palkovic S, Schroeder J, Moustakis C, Bruns F, Schuck A, Wussmann H, Willich N: 12 years' experience with intraoperative radiotherapy (IORT) of malignant gliomas. Strahlenther Onkol 2005, 181:500-506.

68. Nemoto K, Ogawa Y, Matsuhashi N, Takeda K, Takai Y, Yamada S, Kumaie T: Intraoperative radiation therapy (IORT) for previously untreated malignant gliomas. BMC Cancer 2002, 2:1.

69. Hara A, Nishimura Y, Sakai N, Yamada H, Yanagawa S: Effectiveness of intraoperative radiation therapy for recurrent supratentorial low grade glioma. J Neurooncol 1995, 25:239-243.

70. Shibamoto Y, Yamashita J, Takahashi M, Abe M: Intraoperative radiation therapy for brain tumors with emphasis on retreatment for recurrence following full-dose external beam irradiation. Am J Clin Oncol 1994, 17:396-399.

71. Ortiz U, Santos M, Garcia-Berrocal I, Bustos JC, Sambias J, Gutierrez-Diaz JA, Delgado JM, Doncakster G, Calvo FA: Intraoperative radiotherapy in malignant glioma: early clinical results. Neuronal Res 1995, 17:289-294.

72. Wurm RE, Kuczer DA, Schleifer L, Matnjani G, Scheffer D, Cosgrove VP, Ahsewed J, Wociejewskis C, Budach V: Hypofractionated stereotactic radiotherapy combined with topotecan in recurrent malignant glioma. Int J Radiat Oncol Biol Phys 2006, 66:526-532.

73. Glass J, Silverman CL, Axelrod R, Corn BW, Andrews DW: Fractionated stereotactic radiotherapy with cis-platinum radiosensitization in the treatment of recurrent, progressive, or persistent malignant astrocytoma. Am J Clin Oncol 1997, 20:226-229.

74. Lederman G, Wronski M, Arbit E, Odaimi M, Wertheim S, Lombardi E, Wrzolek M: Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel. Am J Clin Oncol 2000, 23:155-159.

75. Arciussa M, Roncadin M, Bidoli E, Dedkov A, Gigante M, Trovo MG: Reirradiation and lomustine in patients with relapsed high-grade glioma. Int J Radiat Oncol Biol Phys 1999, 43:789-793.

76. Caisterlain MC, Baroda D, Karrnunik P, Benson AM, Saunders WM, Shea MC: Concurrent cisplatin therapy and iodine 125 brachytherapy for recurrent malignant brain tumors. Arch Neurol 1995, 52:162-167.

77. Wust P, Hildebrandt B, Sreenivas G, Rau B, Gellerman J, Riess H, Felix R, Schlag PM: Hyperthermia in combined treatment of cancer. Lancet Oncol 2002, 3:487-497.

78. Wust P, Rau B, Gellerman J, Pegios W, Loffel J, Riess H, Felix R, Schlag PM: Radiochemotherapy and hyperthermia in the treatment of rectal cancer. Recent Results Cancer Res 1998, 146:175-191.

79. Sneed PK, Stauffer PR, McDermott MW, Diederich CJ, Lamborn KR, Prados MD, Chang S, Weaver KA, Spry L, Malec MK, Lamb SA, Voss B, Davis RL, Wara WM, Larson DA, Phillips TL, Guitin PH: Survival benefit of hyperthermia in a prospective randomized trial of brachytherapy boost +/- hyperthermia for glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1998, 40:287-295.

80. Schulz-Ertner D, Nikoghosyan A, Thilmann C, Haberer T, Jakel O, Karger C, Kraft G, Wannenmacher M, Debus J: Results of carbon ion radiotherapy in 152 patients. Int J Radiat Oncol Biol Phys 2004, 58:631-640.

81. Schulz-Ertner D, Nikoghosyan A, Dindinger B, Munter M, Jakel O, Karger CP, Debus J: Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques. Cancer 2005, 104:338-344.

82. Mizoe J, Tsuji H, Hasegawa A, Takagi R, Yanagi T, and Takakura K: Carbon ion radiotherapy for malignant gliomas. Sixth Meeting of the European Association for NeuroOncology, Edinburgh, UK, 05-08 May, 2005 2005, Abstract #421.:.

83. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, Shank B, Solin L, Wesson M: Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991, 21:109-122.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1471-2407/7/167/pre-pub